The report highlights Biogen's commitment to advancing neurological research, serving humanity, and fostering a more equitable and sustainable future. The company achieved several key milestones in 2021, including the FDA approval of ADUHELM®, the first new therapy approved for Alzheimer's disease since 2003; the expansion of its SPINRAZA® program, which now serves more than 11,000 people worldwide; and the launch of its Healthy Climate, Healthy Lives™™ initiative, a 20-year, $250 million commitment to advancing climate, health and equity. The report also details the company's efforts to improve diversity, equity, and inclusion throughout the organization, and to build a more sustainable supply chain.
Issuing Company Biogen Inc.
Report Type Sustainability Report
Report Language EN
Report Filesize 7.18 MB
No. of Pages 158 pages
Reporting periodJanuary 1, 2021-December 31, 2021
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; UN SDGs; others
Materiality Assessmenttrue